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Abstract: Primary adrenal insufficiency (PAI) is a potentially life-threatening condition that can
present with non-specific features and can be difficult to diagnose. Here, we undertook
next-generation sequencing in a cohort of children and young adults with PAI of
unknown etiology from around the world and identified a heterozygous missense
variant (rs6161, c.940G>A, p.Glu314Lys) in CYP11A1 in 19 individuals from 13
different families (allele frequency within undiagnosed PAI in our cohort 0.102 vs
0.0026 in gnomAD, p<0.0001). Seventeen individuals harbored a second heterozygous
rare disruptive variant in CYP11A1 and two patients had very rare synonymous
changes in trans (c.990G>A, Thr330=; c.1173C>T, Ser391=). Although p.Glu314Lys is
predicted to be benign and showed no loss-of-function in an E. coli assay system, in
silico and in vitro studies revealed that the rs6161/c.940G>A variant, plus the
c.990G>A and c.1173C>T changes, affect splicing and that p.Glu314Lys produces a
non-functional protein in mammalian cells. Taken together, these findings show that
compound heterozygosity involving a relatively common and predicted “benign” variant
in CYP11A1 is a significant contributor to PAI of unknown etiology, especially in
European populations. These observations have implications for personalized
management and demonstrate how variants that might be overlooked in standard
analyses can be pathogenic when in combination with other very rare disruptive
changes.
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Dear Editor 
We thank the reviewers for their constructive comments. We have addressed the majority of these 
and revised the manuscript accordingly.  
In particular, we have provided more extensive details about the cohorts studied so that the 
prevalence of our findings can be seen within the context of undiagnosed primary adrenal 
insufficiency and also within the context of our total cohort numbers. We include these new data in 
Supplementary Table 2 and have re-written the relevant sections of the manuscript. We feel this 
approach strengthens the significance of our findings considerably.  
As requested, we have also undertaken further functional studies of the CYP11A1 variant in a 
mammalian cell system (HEK cells). These new data suggest the L335P and R460W variants along 
with the E314K have minimal enzyme activity.  
Reviewer Comments: 
Reviewer 1: Maharaja et al describe novel CYP11A1 variants in 19 patients manifesting with primary 
adrenal insufficiency (PAI). Novel aspect is that they show that a variant previously predicted as 
benign and synonymous variants in the CYP11A1 sequence were found to be disease-causing 
through misplicing. Importantly, these variants were found quite often in their unique cohort of 
unsolved PAI (explaining about 10%). 
 
1. The study is performed in a convincing way regarding genetic work-up. For functional work-up the 
only missing experiment is the demonstration that the variants transfected into a cell system (e.g. 
HEK-293 cells) have lower or lost enzyme activity. This would be particularly interesting for the 
p.Glu314Lys mutation, which is shown to be degraded in cells, but has similar activity to wild-type 
when tested as recombinant protein expressed in E. coli. 
We have now performed the functional studies of mutations E314K, L335P, and R460W in V79 cells, 
which are preferable to HEK293 cells for mitochondrial P450 enzyme activity assays. The R460W 
mutation has <1% of wild-type activity in this system, whereas the E314K and L335P mutations have 
no demonstrable activity, based on lack of time-dependent increase in pregnenolone formation. 
These data and the related methods are now included in the manuscript. 
 
2. Why did these patients having cortisol deficiency have a non-ketotic hypoglycemia (manuscript 
text e.g. line 406). Usually, cortisol and growth hormone deficiency manifest with ketotic 
hypoglycemia, while insulin excess causes a non-ketotic hypoglycemia. In Table 1, ketotic 
hypoglycemia is noted with several patients - please check for this inconsistency. 
We thank the reviewer for noticing this error. It should be ketotic hypoglycaemia, not non-ketotic. 
We have corrected this in lines 345 and 447.  
 
3. For Table 1: It would be interesting to give not only the age at presentation, but also the age when 
the clinical and biochemical characteristics as shown were assessed (or does it anyhow reflect the 
same time point?) 
In Table 1 we have focussed on the “Age at Diagnosis” as this is the most reliable time point that can 
be defined, especially as several children had their diagnosis facilitated once adrenal insufficiency 
was diagnosed in a sibling (as noted in the “Presentation” column; 5B, 10A, 11B , 11C and also 
relevant for 8A and 8B).  
Point-by-Point Rebuttal
The biochemical data primarily relate to this time point, unless otherwise indicated in parentheses, 
and we have clarified this in a footnote.  
The age when gonadal function was assessed is also shown in parentheses.  
Clearly the onset of symptoms may have a somewhat indolent course with hyperpigmentation or 
failure to thrive as is typical for adrenal insufficiency, but this is more difficult to define. Of interest, 
subject 5B had mild progression and did not start treatment until 24 years of age as shown in the 
table. This is clarified in a footnote too. 
We have clarified the results to read “Diagnosis occurred at variable ages…” (line 342, instead of 
“Presentation..”) and stated the number of children who’s diagnosis was aided because of family 
history: “In six children or young people (6/19, 32%) the diagnosis was facilitated because of a 
history of PAI in their siblings” (line 343-4) 
Reviewer 2: 
The authors present a CYP11A1 variant, which appears to be present in a significant number of cases 
with mild to moderate P450scc deficiency. The paper provides some explanation of the underlying 
mechanism causing P450scc deficiency. There are, however, experiments lacking which investigate 
the impact on CYP11A1 activity in cell culture. 
 
The authors claim their findings will have implications for personalised management. They fail, 
however, to specify how their molecular findings will improve management in patients. There are 
serious doubts that medical management of adrenal insufficiency has been changed after the 
molecular diagnosis has been achieved. They should provide evidence for improved outcomes. 
We believe there are concrete examples of where the molecular diagnosis of adrenal insufficiency 
has implications for the management of an individual and their family.  
Examples include  
1) withdrawing mineralocorticoids in children with classic FGD due to MC2R mutations, who were 
misdiagnosed with adrenal hypoplasia;  
2) investigating for associated features that may not be immediately apparent and could be treated 
earlier (e.g. gonadotropin insufficiency and spermatic defect in X-linked adrenal hypoplasia; renal 
dysfunction and associated anomalies in SGPL1; being aware of other features and myelodysplastic 
syndrome risk in SAMD9/MIRAGE syndrome; monitoring for progressive gonadal dysfunction and 
offering semen analysis in non classic congenital lipoid adrenal hyperplasia due to partial STAR 
defects; and diagnosing X-linked adrenal leukodystrophy with the potential option of stem cell 
transplant to prevent neurological deterioration) 
3) defining the inheritance pattern and identifying individuals in a presymptomatic state before the 
onset of adrenal insufficiency; knowing the molecular genetic basis is important as these conditions 
can be X-linked, recessive, dominant or imprinted.  
In this study, defining the molecular basis lead to an earlier diagnosis in 6 of the 19 patients (6/19, 
32%) and the potential effect of partial CYP11A1 deficiency on gonadal function means that they will 
be monitored in the long-term for sex steroid and gonadotropin levels, replaced if necessary, and 
early reproductive interventions such as sperm banking offered.  
 
It would be useful to insert subheadings into the results and discussion. The paper can be shortened. 
We have inserted subheadings into the results section. We believe that subdividing the Discussion is 
not house style for JES but would do so if requested by the Editors.  
We appreciate that the paper is long but have included full experimental details, as this is an online 
journal with fewer print restrictions. 
 
Page 4: The cohort has not been specified. It would be vital to understand the overall number of 
patients of this cohort and the overall distribution of other gene defects in relation to the described 
CYP11A1 variants. Thus, the overall relevance to ALL patients with PAI remains questionable. 
Thank you for this comment. This is a very valid point as data were not presented clearly in the 
original submission. We have reanalysed all data from our cohorts and now include this in the 
manuscript.  
Our original manuscript focused on PAI of unknown etiology and clear inclusion and exclusion 
criteria were given. However, total numbers of individuals (and families) were not given clearly, so 
we have provided these data in the relevant methods and results sections, and in new 
Supplementary Table 2. The relevant sections of the manuscript have been re-written. Overall, these 
data have strengthened our argument and more than 20% of children with PAI of unknown etiology 
have this partial CYP11A1 c.940G>A diagnosis. 
We have also analysed the data for our cohorts as a whole and provide these findings in 
Supplementary Table 2.  When we include those children with a genetic diagnosis of PAI due to 
other forms of FGD/adrenal hypoplasia, the partial CYP11A1 c.940G>A diagnosis still accounts for 
more than 4%. We hope we have clarified the importance of this finding now.  
 
Line 226: Please introduce Adx. 
“Adx” has been changed to “adrenodoxin (Adx, ferredoxin)” now at line 246 
 
Line 297: Subjects have not been described in detail. 
We have re-written this section (lines 325-337) based on a better description of the cohort in the 
methods and inclusion and exclusion criteria (lines 110-129).  
Lines 310-316: Please provide a better description including number of patients with specific 
features. 
We have provided most details of clinical features in Table 1 rather than as individual case histories. 
However, we have included specific numbers of children with each feature as requested (lines 342-
349). We agreed this section was too vague before and is more robust with numbers. This paragraph 
has been re-written to state: 
“Clinical details for affected individuals are shown in Table 1. Diagnosis occurred at variable ages 
between 6 months and 16 years. In six children or young people (6/19, 32%) the diagnosis was 
facilitated because of a history of PAI in their siblings. Hyperpigmentation was often present at the 
time of diagnosis (13/19, 68%), and many children had a history of ketotic hypoglycemia or 
hypoglycemic convulsions (10/19, 53%). All children were treated with glucocorticoid replacement 
and almost half of them had received mineralocorticoid replacement (8/19, 42%). Most children 
developed normally in puberty although four boys experienced pubertal delay (4/9 postpubertal 
males, 44%) and mildly elevated gonadotropin concentrations were found in several adults. “ 
 Page 14: It remains unclear, why the CYP11A1 enzyme activity has not been assessed in HEK cells. 
This would have provided direct evidence if the enzymatic function is impaired in a cell culture-
based assay. 
The treatment with cycloheximide is a very crude method. Ideally a pulse chase assay should have 
been performed. It is also unclear why the protein used for the activity assays has not been tested 
for its stability. 
To address this question, we have performed the activity assays in V79 hamster lung cells as 
described in the responses to point 1 for reviewer 1. 
 
Lines 373-374: This sentence appears confusing. PAI commonly requires mineralocorticoid 
replacement and only glucocorticoid therapy. 
We have rephrased this to read: “Glucocorticoid replacement is central to the management of PAI, 
with some patients also requiring mineralocorticoid replacement” 
 
Lines 375-376: Please specify the percentage of unknown cases in the overall cohort and the 
proportion of the novel CYP11A1 variant. 
These data have now been included (see above) and are shown in Supplementary Table 2. 
 
Line 395: It would be crucial to understand the relation of the stated 10%. Are these unsolved cases 
or the overall cohorts of all investigators? 
We agree this was unclear. We have reanalysed our cohorts and now provide exact figures.  In our 
total cohort the prevalence of PAI due to this variant was 20.8% (16/77) in individuals with PAI of 
unknown etiology and 4.1 % (16/395) overall once those with an established genetic diagnosis were 
included. These figures were higher when individuals of European ancestry were considered. 
 
Lines 435-440: The conclusions are not backed by the data. The problems with prediction software 
are well recognised. 
We conclude that the rs6161 change in conjunction with another loss-of-function allele is 
responsible for a significant proportion of unsolved PAI especially in European populations. This is 
backed by the data.  
‘Indeed, many of the subjects reported here had a diagnostic odyssey with some taking many years 
to receive a genetic diagnosis, possibly due to their non-classical presentations.’ We have removed 
this sentence.  
The problems with prediction software are well recognised in some circles but there is an 
overreliance on common prediction tools such as SIFT and PolyPhen to predict the consequence of 
discovered variants. We have altered the sentence to read  
“This study highlights the limitations of relying on common in silico prediction tools and the 
necessity for individual assessment of a polymorphism. This assessment should include testing not 
only the protein function in a suitable cell line and assay system but also the consequence(s) of the 
change at nucleic acid level.”   
Table 1: Please provide the glucocorticoid replacement doses. 
The glucocorticoid replacement doses were mostly within the standard range of 10-15 mg/m2/day 
but sometime on the higher side if there was an attempt to supress the ACTH (up to18 mg/m2/day). 
A footnote to this effect has been added to Table 1. 
Figure 1 is of poor quality and not required. 
Figures were incorporated into a pdf generated from a word document. The TIF versions are of much 
higher quality.  
Figure 1 was requested by a previous reviewer, however, we are happy to be guided by the editors 
as to its inclusion.   
Figure 2, A and C are of very low quality and cannot be reviewed. 
We have altered Figure 2, improving part 2A and removing the low quality sequence data in 2C.  
Figure 4: The kinetic parameters have not been determined as claimed in the figure legend. Activities 
have been measured at different substrate concentrations; however, a proper kinetic analysis has 
not been conducted. 
We regret the errors in the legend for Figure 4. Formal kinetic parameters are misleading for the 
CYP11A1 enzyme because the substrates are not truly soluble at these concentrations, and the 
transfer process to the inner mitochondrial membrane is bypassed. Hence, these activities are at 
best estimates, and the purpose of this experiment was to show that the purified E314K enzyme was 
similar to wild-type CYP11A1. We were not intending to imply quantitatively identical activities or 
generate imprecise kinetic parameter estimates. We have therefore amended the figure legend 
appropriately. 
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Although p.Glu314Lys is predicted to be benign and showed no loss-of-function in an E. coli assay system, 58 
in silico and in vitro studies revealed that the rs6161/c.940G>A variant, plus the c.990G>A and c.1173C>T 59 
changes, affect splicing and that p.Glu314Lys produces a non-functional protein in mammalian cells. Taken 60 
together, these findings show that compound heterozygosity involving a relatively common and predicted 61 
“benign” variant in CYP11A1 is a significant contributor to  PAI of unknown etiology, especially in European 62 
populations. These observations have implications for personalized management and demonstrate how 63 
variants that might be overlooked in standard analyses can be pathogenic when in combination with other 64 
very rare disruptive changes. 65 
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 68 
Introduction 69 
The first step in steroidogenesis involves cleavage of cholesterol to pregnenolone by the cytochrome P450 70 
side chain cleavage enzyme (CYP11A1). CYP11A1 is encoded by CYP11A1 and is expressed in key 71 
steroidogenic tissues such as the adrenal gland and gonads. Further tissue-specific enzymatic steps lead to 72 
production of all other steroid hormones. In the adrenal gland, this ultimately results in production of 73 
glucocorticoids (cortisol) and mineralocorticoids (aldosterone) and weak androgens; and in the gonads, 74 
production of sex steroids (estrogen and testosterone). [1] 75 
Complete loss of CYP11A1 prevents biosynthesis of all steroid hormones and was predicted to be 76 
incompatible with life due to the inability of the placenta to maintain a pregnancy without progesterone 77 
production from fetally-derived tissue. [2] However, it has become clear that biallelic mutations in CYP11A1 78 
are compatible with survival to term. Defects in CYP11A1 can cause a range of phenotypes: from classical 79 
CYP11A1 deficiency with severe disruption of adrenal and gonadal steroidogenesis, causing salt-losing 80 
adrenal insufficiency and gonadal hormone deficiency, to very mild phenotypes where only glucocorticoids 81 
are affected (OMIM 613743).  [3-14, Supplementary Table 1] 82 
Massively parallel sequencing (MPS) technologies have expedited discovery of disease-causing variants. 83 
However, assigning causality to identified variants can be complex. When filtering for causal variants, 84 
synonymous changes (which do not affect amino acid coding) may be discarded, without considering their 85 
allele frequency and variants predicted ‘benign’ at the protein level may be deselected too. Further, splice 86 
site changes may only be considered if they alter the canonical GT…AG motifs bordering introns. Such 87 
stringency may result in pathogenic and clinically relevant variants being missed. 88 
Here, we have investigated a large cohort of children and young people with primary adrenal insufficiency 89 
(PAI) of unknown etiology. We show that compound heterozygous variants in CYP11A1 involving rs6161 90 
(c.940G>A; p.Glu314Lys) are surprisingly common, and that altered splicing needs to be considered when 91 
predicted benign or very rare synonymous changes are found.  92 
 93 
Material and Methods 94 
A. Subjects and Sequencing 95 
The main focus of this study was to assess CYP11A1 in subjects with primary adrenal insufficiency (PAI) of 96 
unknown etiology.  97 
The inclusion criteria included evidence of low cortisol, attenuated cortisol response on cosyntropin 98 
stimulation testing, and elevated adrenocorticotropic hormone (ACTH), with clinical signs of cortisol 99 
insufficiency and hyperpigmentation (Table 1).  Some subjects also had elevated plasma renin activity, low 100 
aldosterone and/or electrolyte disturbances (hyponatremia, hyperkalemia) consistent with mineralocorticoid 101 
insufficiency.  102 
The exclusion criteria were any individuals with an established biochemical and/or genetic diagnosis, such 103 
as other forms of congenital adrenal hyperplasia (e.g. 21-hydroxylase deficiency, 11-beta hydroxylase 104 
deficiency, 3-beta hydroxysteroid-dehydrogenase deficiency type 2), autoimmune adrenalitis, metabolic 105 
disorders or physical cause of adrenal insufficiency (e.g. hemorrhage, infection), or known genetic causes of 106 
familial glucocorticoid deficiency or adrenal hypoplasia. Individuals with isolated hypospadias, 46,XY 107 
disorders of sex development and intrauterine growth restriction (<2SDS) with associated adrenal 108 
insufficiency were also excluded. 109 
Patients were recruited from three main cohorts: 1) The “Barts/Royal London Hospital/QMUL” included 43 110 
individuals with PAI of unknown etiology who were assessed by exome sequencing, targeted panel testing 111 
or direct Sanger sequencing; 2) the “UCL/GOSH” cohort included 25 individuals with PAI of unknown 112 
etiology who were assessed by targeted panel testing; and 3) the “Turkish” cohort included 9 individuals with 113 
PAI of unknown etiology who were assessed by targeted panel and exome sequencing. Using this approach 114 
the prevalence of CYP11A1 c.940G>A as a cause of PAI in a cohort (n=77) with no current diagnosis could 115 
be determined (Supplementary Table 2)  116 
In order to establish the prevalence of CYP11A1 c.940G>A as a cause of PAI in these cohorts in general, 117 
total numbers of individuals recruited over the years were calculated (n=395). Although there is considerable 118 
overlap in clinical features, the “Barts/Royal London Hospital/QMUL” cohort (total n=256) focused more on 119 
classic “familial glucocorticoid deficiency” (FGD) (e.g. MC2R, MRAP, NNT, AAAS, STAR, MCM4) whereas 120 
the “UCL/GOSH” cohort (total n=57) was more focused on adrenal hypoplasia (e.g. NR0B1, with potential 121 
non-classic STAR, NNT, and severe MC2R amongst the diagnosis; almost 80% of children receiving 122 
mineralocorticoid replacement). The “Turkish” cohort (total n=82) included a range of diagnosis published 123 
recently (e.g. MC2R, CYP11A1, MRAP, NNT), and represented individuals and families with high 124 
consanguinity. [3] For this analysis individuals with hypospadias or 46,XY,DSD were excluded and children 125 
with classic forms of CAH (e.g. 21-hydroxylase), autoimmune disorders or physical causes would not have 126 
been referred. 127 
Finally, one family (3 individuals) from Australia was included as the diagnosis had been reached by exome 128 
sequencing. This kindred were not included in prevalence figures as they did not form part of a cohort. 129 
a) DNA Samples 130 
Studies were performed with the approval of local ethics committees; Outer North East London Research 131 
Ethics Committee, reference number 09/H0701/12; London-Chelsea NRES Committee, reference number 132 
13/LO/0224; London-Bloomsbury NRES Committee, reference number 07/Q0508/24; the Mater Hospital 133 
Ethics Committee, reference number 1931C.  Following ethical approval and with informed consent, 134 
genomic DNA was extracted from whole blood of affected individuals, plus parents and unaffected siblings 135 
where available. 136 
b) Sequencing 137 
Whole exome sequencing was utilized for subjects 1, 11A, 11B, 11C; CYP11A1 alone was sequenced for 138 
subjects 18 & 19; whilst all other subjects were analyzed by HaloPlex targeted capture array (Agilent, Santa 139 
Clara, CA) [3, 15] (see methods below). Sanger sequencing was employed to confirm segregation of the 140 
variants in kindreds where parents and/or unaffected siblings were available. 141 
c) Exome Sequencing 142 
Subject 1 was sequenced as described previously. [15] For individuals 11A, B and C, exome sequencing 143 
libraries were constructed using the Nextera Rapid Capture Exome (Illumina, San Diego, CA) according to 144 
the manufacturer’s recommendations. Briefly, 50ng of genomic DNA was tagmented (fragmented and 145 
adapter sequences added) by the Nextera transposomes. Tagmented samples were purified and the 146 
fragment size confirmed using Agilent Technologies 2100 Bioanalyser. Libraries were denatured into single-147 
stranded DNA and biotin-labelled probes specific to the target regions were used for the Rapid Capture 148 
hybridization. The pool was enriched for the desired regions by adding streptavidin beads that bind to the 149 
biotinylated probes. Biotinylated DNA fragments bound to the streptavidin beads were magnetically pulled 150 
down from the solution. The enriched DNA fragments were then eluted from the beads and hybridized for a 151 
second Rapid Capture. A second magnetic bead clean up was performed. The final libraries were analyzed 152 
on the 2100 Bioanalyzer and DNA 1000 chip kit (Agilent) to determine the quantity and size of the enriched 153 
fragments. 154 
Massive parallel sequencing was performed with six samples per flow cell lane via the Illumina HiSeq2000 155 
platform and version 3 SBS reagents to generate 100 bp paired-end reads. After demultiplexing, the Illumina 156 
Data Analysis Pipeline software (CASAVA v.1.8.2) was used for initial base calling. Sequence data were 157 
aligned to the current build of the human genome (UCSC Genome Browser, hg19, released February 2009) 158 
via the Novoalign alignment tool (v.2.08.02 1); sequence alignment files were converted by SAMtools 159 
(v.0.1.14) and Picard tools (v.1.42). SNPs and indels were called with the Genome Analysis Toolkit (GATK 160 
v.5506) and annotated by ANNOVAR. 161 
Further analysis of sequence data was performed with custom scripts employing R and Bioconductor. We 162 
retained good-quality SNPs and indels (minimum depth of coverage for SNP calling: >10-fold for 163 
homozygous SNPs, >15-fold for heterozygous SNPs). Additionally, we used variants that passed GATK 164 
Variant Quality Score Recalibration. 165 
Remaining SNPs and indels were assessed according to prediction of potentially damaging consequence 166 
(‘‘nonsynonymous SNV’’ ‘‘splicing,’’ ‘‘frameshift substitution,’’ ‘‘stopgain SNV,’’ ‘‘stoploss SNV’’) by using both 167 
RefSeq and UCSC transcripts. Further filtering excluded SNPs with a minor allele frequency (MAF) > 0.01 168 
observed in NCBI dbSNP (release 137), 1000 Genomes, 1000 Genomes small indels (called with the 169 
DINDEL program), the SNPs of 46Genomes release by Complete Genomics, and other whole exomes from 170 
more than 3000 control samples run internally by similar capture technology. Variants not present in any of 171 
these databases were considered novel. 172 
d) HaloPlex Targeted Gene Panel and Next Generation Sequencing 173 
A custom HaloPlex DNA target enrichment panel (Agilent Technologies Inc) was designed (SureDesign) to 174 
capture 160 known and candidate genes involved in adrenal development and function. All coding exons 175 
and 100 base pairs of intronic flanking sequence were included. The panel covered known genes potentially 176 
causing PAI, congenital adrenal hyperplasia-related genes, potential syndrome-related genes and candidate 177 
genes based on data from biochemical/biological pathways, mouse models of adrenal dysfunction, and gene 178 
expression. [3] 179 
Sequence capture was performed according to the HaloPlex Target Enrichment Protocol version D.5 180 
(Agilent Technologies Inc) for Illumina sequencing. Patient gDNA aliquots (225 ng) were processed in 181 
batches of 24 samples at a time with an enrichment control DNA sample as a positive control. Sequencing 182 
was performed on a MiSeq next-generation sequencer (Illumina Inc). 183 
Sequence alignment and variant calling were performed using SureCall (version 2.0) software (Agilent 184 
Technologies Inc).  185 
e) Sanger Sequencing 186 
Potential disease causing variants were confirmed by PCR and Sanger sequencing. CYP11A1 exons of 187 
interest including intronic boundaries were amplified by PCR using specific primers (Supplementary Table 188 
3). The reaction mixture contained 100 ng DNA template, 1 x PCR buffer, 200 µM each dNTP, 200 nM each 189 
primer and 1 U Taq DNA polymerase (Sigma-Aldrich). Cycling conditions were: 95˚C for 5 mins (1 cycle); 190 
95˚C for 30s, 55˚C for 30s, and 72˚C for 30s (30 cycles); and 72˚C for 5 mins. PCR products were visualized 191 
on 1% agarose gel and sequenced using the ABI Prism Big Dye sequencing kit and an ABI 3700 automated 192 
DNA sequencer (Applied Biosystems, Foster City, CA), in accordance with the manufacturer’s instructions. 193 
f) Sequence Interpretation 194 
Variants were considered highly likely to be pathogenic if they segregated with the phenotype with an 195 
appropriate inheritance pattern within families, were determined damaging or likely damaging by several 196 
bioinformatic prediction models (Ensembl Variant Effector Predictor; SIFT; PolyPhen2; and Mutation Taster 197 
– see URLs) and/or if they had been reported in association with adrenal insufficiency previously. In addition, 198 
novel missense and synonymous changes with a minor allele frequency less than 3% in the Exome 199 
Aggregation Consortium (ExAC) browser (ExAC; Cambridge, MA, http://exac.broadinstitute.org; accessed 200 
February 2018) were considered.  201 
g) In silico Analysis of Variants 202 
Minor allele frequencies (MAF) were determined from Exome Aggregation Consortium (ExAC) and the 203 
Genome Aggregation Database (gnomAD) browsers. The functionality of the variants was assessed at all 204 
levels by variant effect predictor (VEP) and MutationTaster. Splice function was assessed using Human 205 
splicing finder 3.0, SpliceAid and ESEfinder. 206 
h) Statistical Analysis 207 
The difference in allele frequencies between subjects (counting one proband per family to avoid cascade 208 
testing bias) and controls (MAF from gnoMAD non-Finnish Europeans, determined from ExAC data) was 209 
measured by the Chi-square test with Yates’ correction. 210 
B In Vitro Splicing Assay 211 
An in vitro splicing assay was designed using the commercially obtained Exontrap cloning vector pET01 212 
(MoBiTec GmbH, Göttingen, Germany) containing an intronic sequence interrupted by a multiple cloning 213 
site. DNA fragments of interest were amplified using standard PCR protocol and specifically designed 214 
primers (Supplementary Table 4) containing a restriction enzyme target site for XbaI. Cycling conditions 215 
were as follows: 95°C for 5 minutes, 15 x (95°C for 30 seconds, 70°C for 30 seconds (-1°C per cycle), 72°C 216 
for 30 seconds), 30 x (95°C for 30 seconds, 55°C for 30 seconds, 72°C for 30 seconds) and 72°C for 5 217 
minutes. PCR products were sequenced as above, column purified using the QIAquick® PCR Purification Kit 218 
according to the manufacturer’s protocol and cloned into the Exontrap cloning vector pET01 (MoBiTec 219 
GmbH, Göttingen, Germany). Cloned sequences were verified by Sanger sequencing to ensure the 220 
fragment was in the correct orientation using pET01 specific primers (ET PRIM 06 (Forward) 221 
GCGAAGTGGAGGATCCACAAG and ET PRIM 07 (Reverse) ACCCGGATCCAGTTGTGCCA). Wild-type 222 
(pET01-WT) or mutant (pET01-MUT) plasmids were transfected into HEK293 cells using Lipofectamine® 223 
Reagent. Total RNA, obtained from cells 24h after transfection, was subjected to reverse transcription-PCR 224 
(RT-PCR) generating cDNA with primer GATCCACGATGC (MoBiTec®) and amplifying with primers within 225 
the 5ʹ and 3ʹ exons in the pET01 vector; primer 02 GAGGGATCCGCTTCCTGGCCC) and primer 03 (reverse 226 
sequence CTCCCGGGCCACCTCCAGTGCC) (Supplementary Table 5). Amplification products were 227 
assessed on a 2% agarose gel.  228 
C Fibroblasts Isolation, Culture and Expansion  229 
Fibroblast isolation and culture was performed as described previously. [17] Briefly, a 4mm punch biopsy 230 
from the upper arm (patient 1 and his parents) was immediately incubated with isolation medium (DMEM 231 
supplemented with 10% (vol/vol) FBS and 1% penicillin/streptomycin [P/S]) in a 15 ml-falcon tube. 1 square 232 
mm cubes of skin sample were digested using DMEM/high glucose, 20%FBS (vol/vol), 0.25% collagenase 233 
type-I, 0.05% DNAse-I and 1% P/S (Sigma-Aldrich) at 37°C overnight in a 15 ml-falcon tube. After 234 
centrifugation for 5 min at 1000 rpm, the pellet was resuspended in 5 ml of isolation medium before plating in 235 
gelatin coated T25 flasks.  Cells were kept in human fibroblast media (DMEM/High glucose with sodium 236 
pyruvate and L-glutamine, 20% FBS (vol/vol) and 1% P/S).  237 
D RNA Extraction and PCR Analysis.  238 
Total RNA was purified with a RNeasy Mini Kit (Qiagen, 74106). RNase-Free DNase Set (Qiagen, 79254) 239 
was used to eliminate gDNA contamination. 50ng of RNA was incubated with 60ng/µl of random primers for 240 
5 min at 70oC followed by incubation with 500 µM dNTPs, 40 U of RNAse inhibitor, 200 U of M-MuLV RT 241 
and 1X M-MuLV buffer for 10 min at 25oC, 90 min at 42oC and 15 min at 70oC to generate cDNA. PCR 242 
amplifications were performed using 2 ng of cDNA, dNTPs 200 µM and Q5 DNA polymerase (NEB, M0491) 243 
using primers in exons 3 and 6 of CYP11A1 (Supplementary Table 6).  244 
E Protein Expression in Escherichia coli and Purification.  245 
The F2 construct of human CYP11A1, adrenodoxin (Adx, ferredoxin), and ferredoxin reductase was kindly 246 
provided by Professor Walter L. Miller, University of California, San Francisco. [18] From this three different 247 
cDNAs were constructed separately by PCR; A cDNA encoding human CYP11A1 in pcDNA3 was amplified 248 
by PCR to remove 39-amino acid N-terminal mitochondria-targeting sequence and to add a His6-tag at the 249 
C-terminus. The primers were: 11A1-sense 5’-ATACATATGGCGTCTACCCGTTCTCCT-250 
CGCCCCTTCAATGAGAT-3’; 11A1-antisense 5’-AGAATTCTCAGTGATGGTGATGGTG-251 
ATGCTGCTGGGTTGCTTCCT-3’.  The PCR products were then cloned into pET-17b vector via NdeI/EcoRI 252 
restriction sites.  The cDNA for ferredoxin reductase was amplified by PCR to include His6-tag at the C-253 
terminus and cloned into pET-17b via NdeI/EcoRI restriction sites. The primers were: FdR-sense 5’-254 
ATACATATGGCGTCTACCCAGGAAAAGACCCCACAG-3’; and FdR-antisense 5’-255 
AGAATTCTCAATGGTGATGGTGATGGTGGTGGCCCAGGAGGC-GCA-3’. The sequence coding for 256 
mature human Adx (amino acids 62-184) was amplified by PCR to include His6-tag at the N-terminus and 257 
cloned into pLW01 via NcoI/EcoRI restriction sites.  The primers were: Adx-sense 5’-258 
TATACCATGGCACACCATCACCATCACCATTCATCAG-AAGATAAAATAACAGTC-3’, and Adx-antisense 259 
5’-ATGAATTCTCAGGAGGTCTTGCCC-AC-3’. QuikChange Lightning kit site-directed mutagenesis (Agilent 260 
Technologies, Santa Clara, CA) was used to generate the p.Glu314Lys variants for CYP11A1 in both 261 
pcDNA3 and pET-17b.  The primers were: sense 5’-GCAAGATGTCCTTCAAGGACATCAAGGCC-3’; 262 
antisense 5’-GGCCTTGATGTCCTTGAAGGACATCTTGC-3’. Sanger sequencing of plasmid constructs 263 
confirmed the intended site-specific mutations and ensured lack of other substitutions. Wild-type (WT) and 264 
Glu314Lys plasmid DNAs were isolated using a Qiagen (Valencia, CA) maxi prep kit.  265 
Human Adx was expressed in E. coli strain C41(DE3) and purified as described. [19] Human ferredoxin 266 
reductase [20], CYP11A1 WT [19] and Glu314Lys were expressed in C41(DE3) with pGro7 (Thermo Fisher 267 
Scientific) and purified as described previously. [21] Briefly, Fernbach flasks containing 1 liter of Terrific 268 
Broth (supplemented with 0.5 mM 5-aminolevulinic acid for CYP11A1 [Sigma]) with 100 µg/ml ampicillin (and 269 
20 µg/ml chloramphenicol for pGro7) (Sigma) were inoculated with 20 ml of an overnight pre-culture. The 270 
cells were grown at 37°C with shaking at 250 rpm until the A600 reached 1.0-1.4 AU, at which time the culture 271 
was induced with 0.4 mM IPTG (supplemented with 4 g/L arabinose for ferredoxin reductase and P450s) 272 
and grown for 20-48 h at 28°C. After cell lysis with French press in buffer A (sterile phosphate-buffered 273 
saline containing 20% glycerol for ferredoxin reductase and CYP11A1), the recombinant P450 proteins were 274 
solubilized using 1% cholate (Chem-Impex International) and 0.5% NP-40. After centrifugation at 70,000 x g 275 
for 18 min, the supernatant was mixed with 3-5 ml Ni-NTA affinity resin, and polyhistidine-tagged proteins 276 
were eluted with 10 ml 250 mM imidazole, followed by buffer exchange using PD-10 columns. Purified 277 
CYP11A1 preparations showed a specific content of 8–12 nmol P450/mg protein with 3-10% P420. 278 
F Reconstituted Enzyme Assays.  279 
In a 2 ml polypropylene tube, purified human CYP11A1 (10 pmol, WT or Glu314Lys) was mixed with equal 280 
amount of ferredoxin reductase, 40-fold molar excess of Adx, and dilauroylphosphatidyl choline in <10 µL 281 
volume and incubated for 5 min. The reaction mixture was then diluted to 0.2 ml with 50 mM HEPES buffer 282 
(pH = 7.4), 4 mM MgCl2, 0.2% Tween 20, and substrates 22R-hydroxycholesterol (in ethanol) or cholesterol 283 
(in methyl-P-cyclodextrin inclusion complexes). The resulting mixture was pre-incubated at 37 °C for 3 min 284 
before adding NADPH (1 mM) and incubating at 37 °C for another 20 min. The reaction mixture was 285 
extracted with 1 ml dichloromethane, and the organic phase was dried under nitrogen flow. The steroids 286 
were reconstituted in 70 μl of methanol, and a solution of 0.1 ml 100 mM potassium phosphate buffer (pH 287 
7.4) containing 10 μl of cholesterol oxidase (100 units/ml) was added with 3 μl internal standard (1 mM 288 
dehydroepiandrosterone). The mixture was incubated at 30°C for 6 h to convert the product pregnenolone to 289 
progesterone and the internal standard to androstenedione.  The mixture was extracted with 1 ml 290 
dichloromethane, and the organic layer was dried under nitrogen flow. 291 
a) Chromatography, Data Acquisition, and Determination of Kinetic Constants.  292 
Reaction products were analyzed using an Agilent 1260 Infinity HPLC system with UV detector. Extracted 293 
steroid products were dissolved in 20 μl of methanol, and 5 μl injections were resolved with a 50 × 2.1 mm, 294 
2.6 μm, C8 Kinetex column (Phenomenex, Torrance, CA), equipped with a guard column at a flow rate of 0.4 295 
ml/min. A methanol/water linear gradient was used: 27% methanol from 0 to 0.5 min, 39% to 16 min, 44% to 296 
20 min, 60% to 22 min, 71% to 30 min, 75% to 30.5 min, 27% to 33 min. Steroids progesterone and 297 
androstenedione were identified by retention times of external standards chromatographed at the beginning 298 
and ends of the experiments, and the data were processed with Laura4 software (LabLogic) and graphed 299 
with GraphPad Prism 6 (GraphPad Software, San Diego, CA). 300 
b) Immunoblotting 301 
One day prior to transfection, HEK-293T cells were plated in 6 well plates at 50% confluency. The following 302 
day, cells were transiently transfected with 1 µg plasmid DNA/well and 3 µl FuGENE 6 transfection 303 
reagent/well (Promega, Madison, WI). Transfected cells were treated with 25 µM CHX for the specified 304 
amount of time where indicated, and whole cell protein extracts were collected 48 hours after transfection 305 
using RIPA buffer (Sigma-Aldrich) supplemented with mini protease inhibitor tablet (Roche). Lysates were 306 
briefly sonicated for ~10 seconds, centrifuged to remove cellular debris, and resolved (25 µg total protein) on 307 
a 4-20% SDS-PAGE gel (Novex). The proteins were transferred to a PVDF membrane (Millipore, Billerica, 308 
MA), blocked with 5% fat-free milk in Tris-buffered saline with 0.1% Tween-20, and detected by rabbit anti-309 
CYP11A1 at 1:5000 dilution (RRID: AB_2747382; generous gift from Walter Miller [22]) while mouse anti-310 
GAPDH at 1:10000 dilution (RRID: AB_2107426) served as a loading control. Immunoreactive bands were 311 
visualized on film using HRP-conjugated mouse or rabbit secondary antibodies (1:5000, RRIDs AB_330924 312 
and AB_2099233 respectively) in combination with SuperSignal West chemiluminescence substrate 313 
(Pierce/ThermoFisher).    314 
 c) Activity assay in intact cells 315 
V79 hamster lung cells were plated in 12-well plates at ~70% confluency. The next day, cells were 316 
transiently transfected with 1 μg/well pcDNA3-CYP11A1 plasmids (WT or mutations) in triplicate using 317 
TransIT-LT1 transfection reagent (Mirus) according the manufacturer’s instructions. At 24 h post-318 
transfection, cells were incubated with 1 ml of serum-free medium containing 22R-hydroxycholesterol (5 μM) 319 
and DHEA (control steroid, 1 μM). Aliquots of medium were removed at 6 and 24 h, and 0.1 ml of each 320 
sample was mixed with deuterium-labeled internal standards and extracted with 1 ml methyl tert-butyl ether. 321 
Pregnenolone product was converted to the oxime with hydroxylamine in aqueous ammonia and quantified 322 
using tandem mass spectrometry as described [23]. 323 
Results 324 
A Prevalence of the CYP11A1 c.940G>A variant in PAI 325 
Initially we undertook whole exome or targeted panel sequencing in 77 individuals or family members with 326 
PAI of unknown etiology from the three main cohorts studied (see Subjects and sequencing and 327 
Supplementary Table 2).  Sixteen individuals from twelve different families were found to harbor the rs6161 328 
variant in CYP11A1 (chr15:74635368C>T; c.940G>A) together with another very rare heterozygous variant 329 
(Table 2 families 1 to 10; 12, 13), giving an overall prevalence of CYP11A1 c.940G>A associated with PAI of 330 
unknown etiology of 20.8% (16/77) and a prevalence of 4.1% (16/395) in our cohorts of adrenal insufficiency 331 
patients overall (Supplementary Table 2). Even when only one proband was counted per family to avoid 332 
cascade testing bias, the MAF of rs6161 was enriched in our cohort with a frequency of 0.102 (12 out of 59 333 
compared to a minor allele frequency (MAF) of 0.0026 across all gnomAD populations or 0.0042 in non-334 
Finnish Europeans)(Chi-Square p<0.0001).That means approximately 1 in 200 of the population (and 1 in 335 
120 Europeans) are heterozygous carriers of this variant, compared to 1 in 5 of the undiagnosed PAI study 336 
group. Finally, a further family from Australia with three affected individuals, was identified to have this 337 
variant together with a second change and was included in our series (family 11, Table 1). Consequently, 338 
compound heterozygosity of rs6161 with another disruptive variant in CYP11A1 was identified in 19 339 
individuals from 13 families in total. Validation of the variants and segregation with disease was confirmed by 340 
Sanger sequencing in these patients, and in family members where possible, showing that the variants 341 
occurred in trans. [Table 2, Figure 1]. 342 
Clinical details for affected individuals are shown in Table 1. Diagnosis occurred at variable ages between 6 343 
months and 16 years. In six children or young people (6/19, 32%) the diagnosis was facilitated because of a 344 
history of PAI in their siblings. Hyperpigmentation was often present at the time of diagnosis (13/19, 68%), 345 
and many children had a history of ketotic hypoglycemia or hypoglycemic convulsions (10/19, 53%). All 346 
children were treated with glucocorticoid replacement and almost half of them had received mineralocorticoid 347 
replacement (8/19, 42%). Most children developed normally in puberty although four boys experienced 348 
pubertal delay (4/9 postpubertal males, 44%) and mildly elevated gonadotropin concentrations were found in 349 
several adults.  350 
The protein change resulting from the recurrent rs6161, p.Glu314Lys, is predicted benign by commonly used 351 
algorithms such as SIFT and PolyPhen, but ‘disease causing’ by MutationTaster2. Furthermore, the 352 
nucleotide change, in exon 5, is predicted to affect splicing (HSF3.0, ESEfinder) (Supplementary Table 7). 353 
The trans variants were all extremely rare with MAF ranging from zero to 2.2 x10-5 in gnomAD (Table 2). In 354 
many cases the variant resulted in an obviously deleterious effect; either an early stop gain mutation 355 
(p.Arg120Ter, p.Arg439Ter and p.Arg424Ter), a deletion or insertion causing frameshift and premature stop 356 
codon (c.566dupC, c.835delA and c.790_802del) or a canonical splice site change likely to cause skipping 357 
of the adjacent exon giving rise to a prematurely truncated mRNA (c.1158-2A>G and c.426-2A>G). These 358 
alleles are liable to be destroyed by nonsense-mediated mRNA decay (NMD). The missense variants 359 
p.Leu335Pro, seen in two siblings (Family 5) and the p.Arg460Trp, seen in family 13 are in conserved 360 
residues and, on analysis, were predicted deleterious (SIFT) or probably damaging (PolyPhen). However, 361 
most intriguingly, two very rare synonymous variants were observed (c.990G>A and c.1173C>T), with no 362 
predicted amino acid change (Thr330= and Ser391=) in exons 5 and 7 respectively (Figure 1). Both were 363 
designated ‘disease-causing’ by MutationTaster2 and predicted to alter splicing (HSF 3.0 results in 364 
Supplementary Tables 8 & 9).  365 
B Investigation of Splicing  366 
To investigate potential splicing effects of these variants, a series of functional studies were undertaken. 367 
SNP rs6161 (c.940G>A) is within exon 5, 51bp upstream of the natural splice donor site of intron 6, 368 
c.990G>A occurs at the last base of exon 5 and c.1173C>T is within exon 7, 16bp downstream of natural 369 
acceptor site of intron 6 (Figure 1). Utilizing minigene constructs (Figure 2A), the wild-type allele (c.940G) 370 
showed inclusion of exon 5 but the variant allele (c.940A), caused exon skipping (Figure 2B). Similarly, we 371 
showed that variant c.990A caused exon 5 skipping, while variant c.1173T caused the complete skipping of 372 
exon 7 (Figure 2B). Of note, the wild-type exon 7, c.1173C, is also reported to show a degree of exon 373 
skipping in vitro, consistent with the skipping of this exon in certain transcripts (CD013982) reported in Jin et 374 
al. [24] In each instance exon skipping would result in a frameshift and premature translation-termination 375 
codon, p.Ala277AspfsTer11 (for exon 5 variants) and p.Leu387HisfsTer29 (for exon 7 variant), if the 376 
message is not destroyed in vivo by nonsense-mediated mRNA decay. Sanger sequencing of cDNA 377 
fragments confirmed the variant caused the skipping of its containing exon in each case, with no evidence of 378 
cryptic splice site usage (data not shown).  379 
In order to investigate potential splice effects in vivo, we studied genomic DNA and RNA-derived cDNA in 380 
fibroblasts from Subject 1 and his parents. By PCR of exon 5 in genomic DNA it was confirmed that he had 381 
inherited the c.940G>A variant from his mother and the c.990G>A variant from his father (Figure 3A). PCR 382 
of genomic DNA demonstrated that both alleles were equally represented (data not shown). However, at the 383 
RNA level there was complete absence of the c.990A allele, with no exon skipped RNA detected by an RT-384 
PCR from exon 4-6 (Figure 3A) and both patient and father’s sequence showing wild-type c.990G only 385 
(Figure 3B). This finding would be consistent with NMD of the variant RNA species. In contrast, the c.940A 386 
allele showed evidence of skipping of exon 5 alongside production of normally spliced, exon 5 containing, 387 
transcript; in the subject and his mother’s RNA two bands were seen, the upper corresponding to exons 4-5-388 
6 and the lower consisting of a transcript lacking exon 5 (bands at 384 and 223bp respectively in Figure 3A) 389 
(confirmed by Sanger sequencing, data not shown). As expected, the patient’s RNA contains only the 390 
mutant c.940A transcript at this position as the paternal “wild-type” allele has presumably been degraded by 391 
NMD. In the mother both c.940A  and c.940G transcripts are detected with the c.940A being less abundant 392 
than the wild-type, consistent with exon skipping and NMD for the majority of the variant allele (see the 393 
relative height of the peaks for the mutant ‘A’ and wild-type ‘G’ seen in the mother’s RNA) (Figure 3B 394 
arrowed).  395 
C Assessment of Protein Function 396 
Given the likelihood therefore that some of the c.940A (rs6161) transcripts will be translated into protein, we 397 
evaluated the function of the resultant mutant p.Glu314Lys protein. The mutation was recreated by site-398 
directed mutagenesis, expressed in E. coli, and the catalytic activity of CYP11A1 measured by assays of 399 
cholesterol and 22R-hydroxycholesterol conversion to pregnenolone.  Despite the substitution of negatively-400 
charged Glu314 with a positively-charged lysine residue, the mutant enzyme exhibited similar side-chain 401 
cleavage activities to wild-type CYP11A1 with either substrate (Figure 4A, B). However, when cDNA 402 
encoding p.314Lys was transfected into HEK-293 cells the protein was truncated (degraded), and the half-403 
life after cycloheximide (CHX) treatment was much shorter than for WT (Figure 4C). The truncated protein 404 
was consistent in size with potential proteolytic cleavage of the protein around the p.Glu314Lys change and, 405 
taken together with the splicing results, suggests relatively little functional CYP11A1 would be produced from 406 
this allele. To ascertain whether enough protein escapes degradation in intact cells to produce pregnenolone 407 
and to test for activity in the other two identified missense mutations, V79 cells were transfected with 408 
pcDNA3 expression plasmid encoding wild-type CYP11A1 or the three mutations. Pregnenolone formation 409 
from 22R-hydroxycholesterol was measured with tandem mass spectrometry. Mutation p.Arg460Trp 410 
demonstrated <1% of wild-type activity, whereas mutations p.Glu314Lys and p.Leu335Pro yielded no time-411 
dependent pregnenolone formation (Table 3). 412 
Discussion 413 
Primary adrenal insufficiency is a life-threatening condition. Glucocorticoid replacement is central to the 414 
management of PAI, with some patients also requiring mineralocorticoid replacement. Approximately twenty 415 
different genetic causes of PAI have been identified to date (www.icped.org), but in a substantial proportion 416 
of individuals the cause is not currently known.  417 
The enzyme CYP11A1 plays a key role in the initial steps of steroidogenesis by catalyzing the cleavage of 418 
cholesterol to pregnenolone. Children with marked disruption of this enzyme typically present with severe 419 
salt-losing adrenal insufficiency in the first few days of life and a complete block in gonadal steroidogenesis, 420 
with female-typical external genitalia in 46,XY infants or a lack of puberty in 46,XX girls. [3-5, 9-14] More 421 
recently, partial loss-of-function of CYP11A1 has been reported in children with delayed-onset adrenal 422 
insufficiency and hypospadias, or glucocorticoid insufficiency alone. [6-8] The glucocorticoid pathway seems 423 
especially vulnerable to loss of CYP11A1 activity, potentially due to the much higher molar concentrations of 424 
cortisol that are required, and even low levels of residual enzyme activity appear to be sufficient for fetal 425 
gonadal steroidogenesis (Supplementary Table 1. [6-8]. Similar findings have been shown for steroidogenic 426 
acute regulatory protein (STAR), a related protein involved in facilitating cholesterol transfer into 427 
mitochondria, where complete disruption causes congenital lipoid adrenal hyperplasia affecting adrenal and 428 
sex hormones, but partial dysfunction is associated with predominant glucocorticoid insufficiency. [25, 26] 429 
This current study included individuals or families with primary adrenal insufficiency where the current cause 430 
was unknown. In thirteen families (19 affected individuals) massively parallel sequencing revealed the 431 
rs6161 (c.940G>A, p.Glu314Lys) variant in CYP11A1 in compound heterozygosity with another very rare 432 
and/or deleterious variant. We showed that the rs6161 variant and two rare synonymous variants (Thr330= 433 
and Ser391=) can cause missplicing, giving rise to absent or dysfunctional proteins thereby contributing to 434 
the pathogenesis in primary adrenal insufficiency. In our cohort, compound heterozygosity for the c.940G>A 435 
with a second disruptive variant accounted for more than 20% of undiagnosed primary adrenal insufficiency 436 
and was one of the most common causes of familial PAI. Our observations are supported by the recent case 437 
report of compound heterozygosity for c.940G>A with a disruptive splice variant (c.425+1G>A) in a boy with 438 
an indolent presentation of primary adrenal insufficiency from 3 years of age and a history of hypospadias. 439 
[14] Indeed, the relatively high MAF of rs6161 in the population (approximately 1 in 120 Europeans are 440 
carriers) suggests that there is a natural “pool” of this variant in this population and can manifest a 441 
phenotype when in combination with a very rare disruptive variant in trans. Four individuals in gnomAD (out 442 
of 138,595 individuals, or 277190 alleles) are homozygous for rs6161 (c.G>940A) but it is not known 443 
whether this is associated with any adrenal phenotype.  444 
Clinically, the majority of affected individuals reported here were at the mild end of the spectrum, having 445 
been diagnosed with “familial glucocorticoid deficiency” or “Addison’s disease”. For most, onset occurred 446 
during childhood rather than in the neonatal period and hypoglycemic convulsions or ketotic hypoglycemia 447 
were a common feature. Others had a more indolent course during adolescence or were only diagnosed 448 
because of family history and mild symptoms, highlighting the importance of making this diagnosis and 449 
investigating “at risk” individuals. Glucocorticoid insufficiency was common to all affected individuals but 450 
approximately half needed mineralocorticoid (MC) replacement and disordered sex development was not 451 
seen. Three males had delayed puberty, but others progressed through puberty normally, and two older 452 
males have fathered children. However, monitoring of MC activity and gonadal function will be needed for 453 
long term management, and more detailed long-term studies will be important to understand the natural 454 
history of this condition. Of note, heterozygous parents appear unaffected, as is usual for disorders of 455 
steroidogenesis. 456 
The rs6161 allele alters splicing of the pre-mRNA sequence with the result that many RNA transcripts do not 457 
include exon 5. The transcripts that do include exon 5 will give rise to a mutant protein with an amino acid 458 
change, glutamic acid to lysine, at residue 314. Although the mutation reverses the charge on this side chain 459 
from negative to positive, the residue is located on the surface of the protein in the I-helix facing solvent and 460 
has no effect on protein function. Given this ambiguity, we went on to show that the purified p.314Lys 461 
mutation has normal spectral and catalytic properties in E. coli but gives rise to an unstable truncated protein 462 
of 30-35kDa when expressed in mammalian cells. In vivo, in affected individuals, it is likely that the 463 
combination of defective splicing and protein dysfuction will result in low levels of functional, full-length 464 
protein derived from this allele. This may be sufficient for gonadal steroidogenesis but insufficient for 465 
glucocorticoid production. Furthermore, our studies have only been possible in skin fibroblasts or non-466 
steroidogenic cells, so it is possible that higher residual function occurs in the adrenal gland or gonad.  467 
Tools for prediction of the functional effects of non-synonymous variants are well-established [27], but these 468 
may not predict the effect such changes have on splicing. In particular, variants causing benign amino acid 469 
changes may have their effect on mRNA processing or post-translational modification. Synonymous or 470 
‘silent’ changes are often ignored and, when tested, commonly used prediction tools may prove inconclusive. 471 
Up to 45% of synonymous SNPs are likely to alter pre-mRNA splicing and regulatory information may be 472 
dispersed throughout nearly every nucleotide in an exon [28, 29], making it important to consider them in 473 
variant analyses, especially when very rare and discovered in known or likely causative genes.  474 
Conclusion  475 
We conclude that the rs6161 change in conjunction with another loss-of-function allele is responsible for a 476 
significant proportion of unsolved PAI especially in European populations. This study highlights the 477 
limitations of relying on common in silico prediction tools and the necessity for individual assessment of a 478 
polymorphism. This assessment should consider not only the protein function in a suitable cell line and 479 
assay system but also the consequence of the change at nucleic acid level.   480 
 481 
Appendix 482 
Web Resources; 483 
Human Splicing Finder 3.0 http://www.umd.be/HSF3/ 484 
Mutation Taster http://www.mutationtaster.org/  485 
PolyPhen-2 http://genetics.bwh.harvard.edu/pph2/  486 
Sorting Intolerant from Tolerant (SIFT) http://provean.jcvi.org/genome_submit_2.php  487 
dbSNP, www.ncbi.nlm.nih.gov/SNP/  488 
Exome Aggregation Consortium (ExAC), Cambridge, MA (URL: http://exac.broadinstitute.org) [Accessed 489 
February 2018]. 490 
The Genome Aggregation Database, http://gnomad.broadinstitute.org/ [Accessed February 2018]  491 
Variant effect predictor http://www.ensembl.org/Tools/VEP   492 
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org/ 493 
The Human Gene Mutation Database: http://www.hgmd.cf.ac.uk/ac/index.php 494 
Ingenuity variant analysis: http://www.ingenuity.com/ 495 
Otogenetics: http://www.otogenetics.com/ 496 
ESEfinder 3.0 http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home 497 
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Figure Legends 598 
Figure 1. Position of variants in CYP11A1 genomic/pre-mRNA sequence found in this series of PAI 599 
patients.  600 
Boxed in bold the three predicted benign or synonymous variants assessed for their effect on splicing; SNP 601 
rs6161 (c.940G>A, p.Glu314Lys) is 110bp from the start and 51bp from the end of exon 5, c.990G>A 602 
(p.Thr330=) occurs at the last base of exon 5 and c.1173C>T (p.Ser391=) is 16bp from the start of exon 7. 603 
Figure 2.  An in vitro assay reveals aberrant splicing of variants c.940G>A, c.990G>A and c.1173C>T.  604 
(A) Minigene construction. Diagram of exon 5 and parts of flanking introns 4 and 5, inserted into the 605 
multiple cloning site (MCS) of the pET01 construct (lower). In the pET01 construct, the intron containing the 606 
MCS is flanked by the 5ʹ-donor and 3ʹ-acceptor splice sites of pre-proinsulin 5ʹ and 3ʹ exons, respectively 607 
(green arrows) (http://www.mobitec.com/cms/products/bio/04_vector_sys/exontrap.html). The expression of 608 
this vector sequence was driven by the promoter present in the long terminal repeat (LTR) of Rous Sarcoma 609 
Virus followed by a short stretch of a eukaryotic gene (phosphatase). The sequences containing the 610 
mutations detected in CYP11A1 exons 5 and 7 (MUT) or those that did not (WT) were cloned into the MCS 611 
of pET01. The primers used in the reverse transcription-PCR (RT-PCR) experiments within the preproinsulin 612 
5ʹ and 3ʹ exons are indicated by the black arrows (Supplementary Table 5). (B) Representative results of RT-613 
PCR analysis using HEK293 cells transfected with an empty pET01 vector (empty vector), the pET01 vector 614 
containing the wild-type exon or the mutant exon; on the left the c.940A in exon 5, in the middle the c.990A 615 
change in exon 5, on the right the C.1174T change in exon 7. A transcript of 225bp was observed in the 616 
empty and mutant vector RT-PCRs, for all variants investigated, corresponding to the two-exon amplification 617 
product resulting from splicing of the preproinsulin 5’ and 3’ exons from the vector. For wild-type vectors 618 
containing c.940G and c.990G, a 386 bp transcript was observed corresponding to the three-exon 619 
amplification product resulting from correct splicing of CYP11A1 exon 5 between the two vector exons. The 620 
intermediate band for exon 5 constructs, at approximately 350bp (asterisked), was shown to be a mixture of 621 
sequence including both the 386 and 225 bp bands. For wild-type c.1173C, a 304bp transcript 622 
corresponding to the size of the three-exon amplification product resulting from correct splicing of CYP11A1 623 
exon 7 was observed. Sanger sequencing confirmed these findings (data not shown).  624 
  25 
Figure 3. Sequence analysis of in vivo splicing in patient 1 and his parents. (A) RT-PCR amplification 625 
products utilising primers in exons 4 and 6 of CYP11A1. Lanes 1 and 2, patient 1 and his mother show two 626 
bands corresponding to transcripts containing exon 5 (upper band) and skipping exon 5 (lower band), this 627 
was confirmed by Sanger sequencing. In contrast, in lane 3 the father shows only the upper, exon 5 628 
containing, transcript. (B) Partial chromatograms from Sanger sequencing of the upper bands in the patient, 629 
mother and father. For the c.990G>A change (on the right) the patient and father’s sequence reveals only 630 
the wild-type c.990G (white arrows), suggesting that the c.990A variant results in exon skipping and the 631 
destruction of the truncated mRNA by NMD. For c.940G>A (on the left) the patient’s sequence only has the 632 
mutant c.940A allele A inherited from his mother (black arrow), corroborating the NMD destruction of the 633 
c.990A allele inherited from his father, since if it were present it would give a heterozygous base at this 634 
position. In contrast the mother’s sequence shows both wild type G and a small peak of the mutant A (black 635 
arrow) consistent with skipping of mutant exon 5 in most mutant transcripts but revealing the presence of 636 
some transcripts containing exon 5.     637 
Figure 4. The p.314Lys protein evaluation.  A. Side-chain cleavage activity of CYP11A1 mutant p.314Lys 638 
is unaltered in E. coli.  Expressing the purified mutant protein in E. coli, showed comparable activity (black 639 
bars) as the wild-type enzyme (grey bars). The activity of the mutant p.314Lys was determined to be 640 
indistinguishable from wild-type protein whether the substrate was 22R-hydroxycholesterol (left panel) or 641 
cholesterol (right panel). B. The p.314Lys variant exhibits altered protein expression compared to wild-type 642 
when expressed in HEK-293T cells. HEK-293T cells were transiently transfected with either wild-type 643 
CYP11A1 or p.314Lys constructs and cultured for 48 hours. For the indicated times prior to protein 644 
collection, the cells were treated with 25 µM CHX. Whole cell lysates were analyzed by immunoblot and 645 
probed with anti-CYP11A1 and anti-GAPDH antibodies. For the wild-type, a full-length protein was observed 646 
at 60kDa, whereas for the p.314Lys mutant, the protein was truncated to 30-35kDa, consistent with a 647 
cleavage event around the site of the amino acid change. Cycloheximide treatment revealed the mutant 648 
protein also has a shorter half-life.  649 
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Table 1. Clinical presentation of 19 individuals with CYP11A1 mutations  
Subject Sex Age at 
diagnosis
a 
Presentation Replace
ment 
ACTH at 
presentation 
(pg/ml) 
Cortisol at 
presentation 
(peak 
stimulated) 
(nmol/l) 
Na/K 
(mEq/l) 
Plasma 
renin 
activity 
(ng/ml/h 
unless 
stated) 
Aldoste
rone 
(pmol/l
) 
Puberty FSH (iU/L) /LH 
(iU/L) 
/testosterone 
(nmol/l)/oestr
adiol (pmol/l) 
Comments 
1 M 10y Hypoglycemic 
convulsions, 
vomiting, 
hyperpigmentation 
GC 149 234 (peak 118) 142/4.4 2.0 (<3.0)  300 Normal FSH 3.4, LH 
4.1, 
testosterone 
14.8 (21y) 
Originally 
diagnosed with 
ketotic 
hypoglycemia. 
Published in Chan 
et al. (15) 
2 M 9m Hypoglycemia 
(ketotic) 
GC 1002 93 N N ND Delayed 
then 
progressed 
N Fertile 
3 F 11m Failure to thrive, 
anorexia, 
hyperpigmentation 
GC >1500 190 N ND 496 Normal ND Brother died age 
3y with similar 
features 
4 M 11m Pneumonia, 
hypoglycemia, 
collapse 
GC, MC 155 (had been 
on treatment) 
90 (peak 264) 132/4.0 5.3 ND Normal FSH 9.0, LH 
7.4, 
testosterone 
20.3 (16y) 
  
5A F 16y Secondary 
amenorrhea/galact
orrhea, pituitary 
corticotrope 
adenoma, 
hyperpigmentation 
GC 3354 108 (peak 154) ND 2.4 1136 Normal 
(secondary 
amenorrhea
) 
N Pituitary 
macroadenoma, 
prolactinemia. 
Published in 
Benoit et al. (16) 
5B F 14y b Investigated as 
sister diagnosed 
GC 
(24y) 
400 276 (peak 303) ND N 416 Normal  ND - 
Table 1 Click here to access/download;Table;Final for resubmission table 1v2.doc
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6 M 4y Recurrent illnesses, 
hyperpigmentation 
GC, MC 1147 252 (peak 79) 133/5.4 ND ND Delayed 
then 
progressed  
FSH 18.3, LH 
9.1 (16 years); 
FSH 9.0, LH 
6.1, 
testosterone 
13.2 (25y) 
- 
7 M 7y Recurrent illnesses, 
hyperpigmentation 
GC, MC 1091 31 N 89.4/202 
mU/l 
<100 N/A 
(prepubertal
) 
N/A - 
8A M 9y Convulsions, 
hyperpigmentation
, younger brother 
diagnosed 
GC, MC 6128 (23y) 339 (peak 389) 137/3.5 9.7 (23y); 
83.5 
miU/l 
(<40) 
(38y) 
ND Delayed 
then 
progressed 
FSH 13.8, LH 
5.8, 
testosterone 
24.7 (38y) 
- 
                          
8B M 8y Convulsions, 
hyperpigmentation
, younger brother 
diagnosed 
GC, MC 264 (17y) (on 
treatment)  
278 (peak 301) 141/3.6 10.2 
(21y) 
ND Delayed 
then 
progressed 
FSH 9.3, LH 
5.4, 
testosterone 
33.3 (36y) 
- 
8C M 1.5y Febrile convulsions, 
hypoglycemia, 
hyperpigmentation 
GC, MC 4356 174 (peak 178) 129/5.9 20.9  
(<2.0) 
(17y); 
119.2 
miU/l 
(<40) 
(32y) 
ND Normal FSH 41.2, LH 
33.9, 
testosterone 
27.2 (32y) 
- 
9 M 2y Hypoglycemia, salt-
wasting, 
hyperpigmentation 
GC, MC 463 157 127/6.8 ND <100 Normal FSH 14, LH 15, 
total 
testosterone 7 
ng/ml (15y) 
- 
10A F 15y Investigated as 
brother diagnosed 
GC 67 129 (peak 279) 141/4.2 2.5 (0.5-
3.1) 
380 Normal N   
 3 
10B M 5y Recurrent illnesses, 
ketotic 
hypoglycaemia, 
hyperpigmentation 
GC 385 116 (172) N (Na128 
vomiting) 
3.1 (<7.0) 140 N/A 
(prepubertal 
N/A   
11A F 4y Hypoglycemic 
seizure, cardiac 
arrest, died 
GC >1250 73 ND ND ND N/A (died) N/A (died; 
normal ovaries 
on autopsy) 
Autopsy: small 
adrenals with 
normal zona 
glomerulosa and 
atrophied zona 
fasciculata 
11B F 2y Hyperpigmentation
, elder sister 
diagnosed 
GC 686 Peak 55 140/4.0 45 mU/l 
(3-35) 
155 Normal  FSH 3.6, LH 
3.2, estradiol 
200 (14y) 
Hypertension 
treated with 
captopril; small 
adrenal glands on 
CT 
11C M 11m Investigated as 
sister diagnosed 
GC 350 226 (276) 137/4.1 70 mU/l 
(3-35) 
(14y) 
227 
(14y) 
Normal FSH 14, LH 4.5, 
testosterone 
14 (14y) 
Hypertension 
treated with 
Ramipril. Also 
treated for 
steroid 
responsive 
nephrotic 
syndrome 
(minimal change 
disease) 
12 F 6m Hyperpigmentation GC 2896 14 (14) ND 54 ng/l 
(<150) 
97 N/A 
(prepubertal
) 
N/A  
13 F 3y Hypoglycaemia, 
hyperpigmentation
, lethargy 
GC, MC 1487 64  (with 
blood glucose 
1.6mmol/l) 
131/4.3 27.7  137 N/A 
(prepubertal
) 
N/A  
 
Notes: a Age of diagnosis is shown which corresponds to the age investigations were undertaken unless indicated. b Regular replacement therapy was initiated at a later 
age. ACTH pg/ml x 0.22 for pmol/l, normal range 10-60 pg/ml. Cortisol nmol/l x 0.036 for μg/dl, normal peak stimulated value > 550 nmol/l; plasma renin activity pmol/ml/hr x 
 4 
1.3 for ng/ml/h; aldosterone pmol/l x 0.36 for pg/ml; testosterone nmol/l x 28.9 for ng/dl; estradiol pmol/l x 0.27 for pg/ml. Additional normal ranges are shown as well as age 
at sampling, Some variation may occur due to assay methods and age of the patient. 
Abbreviations: M, male; F, female; y, years; m, months; GC, glucocorticoid; MC, mineralocorticoid; N, within normal range; ND, not done; N/A, not applicable 
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Table 2. Genetic diagnoses in 19 patients with CYP11A1 mutations 
Subject Genomic co-ordinates 
and nucleotide change 
(Genome assembly 
GRCh37.p13) 
cDNA position 
and 
nucleotide 
change 
(transcript 
NM_000781) 
Protein 
(prediction) 
dbSNP/HGMD (if 
annotated) 
Number of alleles 
present In 
gnomAD/number 
sequenced in 
gnomAD 
MAF gnomAD 
Predicted# and/or 
tested 
consequence 
Segregation Country Sequencing method 
rs6161 variant common to all 
  
  
              
All 74635368C>T 940G>A E314K rs6161 
710/277190 
(4 homozygotes) 
0.002561 
 
missense#/skipping 
of exon 5 = 
p.A277Dfs*11 
Yes various various 
Variants in trans with rs6161 
  
  
              
1 74635318C>T 990G>A  T330= NA not seen 
0 
silent#/skipping of 
exon 5 
p.A277Dfs*11 and 
NMD 
Yes UK WES 
2 74635473delT 835delA I279Yfs*10 rs757299093/ 
CD050132  
7/277156 
4.061e-6 
 
early stop# Yes UK HaloPlex 
3 74631031G>A 1315C>T  R439* rs755975808 2/277174 
7.216e-6 
 
 
early stop# Yes Spain HaloPlex 
4 74631641G>A 1173C>T (ND) S391= rs751829641 6/277178 
2.165e-5 
 
silent#/skipping 
exon 7 = 
p.L387Hfs*29 
ND UK HaloPlex 
5A 74632081A>G 1004T>C  L335P NA not seen 
0 
 
missense# Yes France HaloPlex 
5B 74632081A>G 1004T>C  L335P NA not seen 
0 
 
missense# Yes France HaloPlex 
6 74637586T>C c.426-2A>G exon 3 skip rs754329273 2/245202 
8.157e-6 
 
skipping of exon 3# 
resulting in 
p.K142Nfs*3 
ND UK HaloPlex 
7 74631076G>A 1270C>T R424* rs762412759 5/277032 
1.805e-5 
truncation/NMD# ND UK HaloPlex 
Table 2 Click here to access/download;Table;Final for resubmission table 2.doc
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8A 74636157_74636169del c.790_802del K264Lfs*5 NA not seen 
0 
 
early stop# Yes UK HaloPlex 
8B 74636157_74636169del c.790_802del K264Lfs*5 NA not seen 
0 
 
early stop# Yes UK HaloPlex 
8C 74636157_74636169del c.790_802del K264Lfs*5 NA not seen 
0 
 
early stop# Yes UK HaloPlex 
9 74631658T>C c.1158-2A>G exon 7 skip NA not seen 
0 
skipping of exon 7 
resulting in 
p.L387Hfs*29# 
 
ND Turkey HaloPlex 
10A 74640308G>A c.358C>T R120* NA 2/246224 
8.123e-6 
 
early stop ND UK HaloPlex 
10B 74640308G>A c.358C>T R120* NA 2/246224 
8.123e-6 
early stop ND UK HaloPlex 
11A 74635473delT c.835delA  I279Yfs*10 rs757299093/CD050132  7/277156 
4.061e-6 
 
early stop# Yes Australia WES 
11B 74635473delT c.835delA  I279Yfs*10 rs757299093/CD050132  7/277156 
4.061e-6 
 
early stop# Yes Australia WES 
11C 74635473delT c.835delA  I279Yfs*10 rs757299093/CD050132  7/277156 
4.061e-6 
 
early stop# Yes Australia WES 
12 74637444dupG c.566dupC S191Lfs*10 NA not seen 
0 
 
early stop ND Canada CYP11A1 sequencing 
13 74630968G>A c. 1378C>T R460W rs535782968 2/246170 
8.124e-6 
missense# ND UK CYP11A1 sequencing 
Notes: #, predicted consequence of variant at protein level. 
Abbreviations: NA, not applicable; ND, not determined, NMD, nonsense-mediated mRNA decay; WES, whole exome sequencing. 
Table 3. CYP11A1 activity in transfected V79 cells 
 Pregnenolone formed (pg/well) 
CYP11A1    6h   24h 
Wild-type   23238 ± 3919   48113 ± 10369 
R460W   105 ± 28   388 ± 226 
L335P 84 ± 15 73 ± 19 
E314K 83 ± 3 86 ± 30 
 
Table 3 Click here to access/download;Table;Final for resubmission
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